Clinical Trial Update: Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) [Phase 2]

View source ↗

Summary

Open-label Phase 2 trial evaluating SUBA-itraconazole (SUBA-Cap) in Basal Cell Carcinoma in Basal Cell Nevus Syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma in Basal Cell Nevus Syndrome

Drugs mentioned

• SUBA-Itraconazole (itraconazole)

Snippet

Sponsor: HedgePath Pharmaceuticals, Inc. | Conditions: Basal Cell Carcinoma in Basal Cell Nevus Syndrome | Phase 2 | Status: COMPLETED